Celldex Therapeutics Inc

10 de set. de 2026, 19:26 UTC

Celldex Therapeutics Inc shares are lower, reflecting bearish sentiment in the biotechnology sector. The stock remains below its 20-day moving average.

8 de set. de 2026, 20:07 UTC

Celldex Therapeutics Inc shares are lower today, reflecting ongoing performance weakness amid speculation about a potential Federal Reserve interest rate hike.

28 de ago. de 2026, 20:03 UTC

Celldex Therapeutics Inc. shares are lower today, breaking a trend of higher closes. Broader market conditions may be influencing this shift.

24 de ago. de 2026, 20:06 UTC

Celldex Therapeutics is trading higher, reflecting positive sentiment in the biotechnology sector despite no specific company news. Overall movement remains higher since Friday's close.

21 de ago. de 2026, 19:26 UTC

Celldex Therapeutics Inc. shares are higher, maintaining above the 20-day moving average amid a broader market rebound and shifts toward safe-haven assets.

20 de ago. de 2026, 20:01 UTC

Celldex Therapeutics shares are lower as biotechnology stocks face pressure, reflecting a notable decline since Wednesday. Earlier, shares briefly peaked before dropping sharply.

19 de ago. de 2026, 19:26 UTC

Celldex Therapeutics Inc is trading higher during Wednesday's session, maintaining gains since Tuesday's close despite earlier intraday fluctuations.

18 de ago. de 2026, 19:36 UTC

Celldex Therapeutics Inc. shares are lower today amid broader market concerns, including rising treasury yields and inflation fears, despite remaining above the 20-day moving average.

17 de ago. de 2026, 19:16 UTC

Celldex Therapeutics Inc. shares are lower today, retracing from earlier gains amid broader market concerns over economic growth following recent U.S. retail sales data.

14 de ago. de 2026, 20:06 UTC

Celldex Therapeutics Inc shares are lower today amid mixed market sentiment following a decline in U.S. retail sales for July.

13 de ago. de 2026, 20:06 UTC

Celldex Therapeutics shares are lower today, continuing a decline since Wednesday amid rising initial jobless claims in the U.S.

12 de ago. de 2026, 19:56 UTC

Celldex Therapeutics Inc is higher today, maintaining a positive trend after closing up in the last seven sessions. The stock pulled back slightly from an earlier peak.

11 de ago. de 2026, 20:06 UTC

Celldex Therapeutics Inc shares are higher today, marking six consecutive sessions of gains. The stock remains significantly above its 20-day moving average.

10 de ago. de 2026, 19:16 UTC

Celldex Therapeutics shares are higher as Barclays and Morgan Stanley raise price targets to $53.00 and $46.00, respectively, maintaining overweight ratings.

7 de ago. de 2026, 19:11 UTC

Celldex Therapeutics shares are lower despite Morgan Stanley and Barclays raising price targets to $46 and $53, respectively. Broader market volatility persists.

5 de ago. de 2026, 20:01 UTC

Celldex Therapeutics Inc shares are trading higher amid a positive market backdrop, supported by declining oil prices and optimism over U.S.-Iran negotiations.

4 de ago. de 2026, 19:56 UTC

Celldex Therapeutics Inc shares are higher today, supported by overall market strength amid a decline in crude oil prices. No specific company news was identified.

3 de ago. de 2026, 19:53 UTC

Celldex Therapeutics Inc. shares are lower as biotechnology stocks decline. The broader sector's weakness has influenced the stock's price action today.

31 de jul. de 2026, 19:36 UTC

Celldex Therapeutics Inc. shares are lower today amid significant pressure on biotechnology stocks, with no specific company news identified to explain the decline.

30 de jul. de 2026, 18:51 UTC

Celldex Therapeutics Inc is advancing during Thursday's session, moving higher alongside the broader market amid positive macroeconomic sentiment.

29 de jul. de 2026, 20:03 UTC

Wells Fargo raised its price target on Celldex Therapeutics to $72, citing confidence in the company's growth prospects and promising pipeline. Shares are higher today.

28 de jul. de 2026, 19:36 UTC

Shares of Celldex Therapeutics Inc. are lower today, continuing a decline since Monday's close, despite an earlier modest rebound from session lows.

27 de jul. de 2026, 19:31 UTC

Celldex Therapeutics is higher today, bolstered by strong sentiment for its barzolvolimab program and successful Phase 3 enrollment for chronic spontaneous urticaria trials.

22 de jul. de 2026, 20:01 UTC

Celldex Therapeutics is lower after discontinuing barzolvolimab development due to failed trial results. Wells Fargo lowered its price target to $48.

21 de jul. de 2026, 23:01 UTC

Celldex Therapeutics shares fell in after-market hours following disappointing Phase 2 trial results for barzolvolimab, which failed to meet primary and secondary endpoints.